Skip to main content

CSL joins Basel Area biotech cluster

| News

CSL joins Basel Area biotech cluster

02.11.2023

The research and development department of the globally active Australian biotech company CSL has moved into a new office in the Switzerland Innovation Park Basel Area on the Novartis Campus in Basel. With this move, CSL aims to tap into the region's great potential.

At the CSL office opening in Basel (from left to right): Christof Klöpper, CEO Basel Area Business & Innovation, Emmanuelle Lecomte-Brisset, CSL Head of Global Regulatory Affairs, Eric Teo, CSL Head of Patient Safety (Photo by Arianna Ramirez)

CSL is expanding its research and development (R&D) network in Switzerland. The global biotechnology company, which is headquartered in Melbourne, Australia, officially opened a new office in the Switzerland Innovation Park Basel Area premises on the Novartis Campus in Basel. The contract with the operator includes 18 workstations.

In a statement, CSL describes the move as a “pivotal milestone in strengthening CSL’s R&D network across Switzerland”. It allows for “flexible and activity-based ways of working” and taps into “the region’s great potential” for collaboration along the drug development process.

Access to Basel Area’s talent pool

“This step is not only extending our long-standing strategic partnerships with key players in biotech located in Basel but ensuring access to the region’s talent pool and exploring further opportunities for collaboration”, commented Emmanuelle Lecomte Brisset, CSL’s Head of Global Regulatory Affairs who is leading CSL’s efforts to strengthen its R&D presence in Switzerland.

In May of this year, CSL opened an R&D laboratory on the Biopôle Campus in Lausanne. In August 2022, the company acquired Switzerland’s Vifor Pharma, which has since operated as CSL Vifor. CSL has also established collaborations with academic institutions in Switzerland, such as the Swiss Federal Institute of Technology in Lausanne and Lausanne University Hospital.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.